Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down - Here's Why

Key Points

• Zealand Pharma A/S shares gapped down from $71.49 to $65.74 prior to trading, reflecting an 8.0% decline.
• Research analysts have mixed ratings on the stock, with Zacks lowering it to a "strong sell" while others upgraded it to "strong buy."
• The company reported Q2 earnings of $16.06 EPS, which fell short of analysts' expectations of $16.72 and significant revenue expectations of $9.18 billion.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $71.49, but opened at $65.74. Zealand Pharma A/S shares last traded at $65.74, with a volume of 110 shares traded.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ZLDPF shares. Zacks Research lowered Zealand Pharma A/S from a "hold" rating to a "strong sell" rating in a research report on Friday, August 15th. Wells Fargo & Company raised Zealand Pharma A/S to a "strong-buy" rating in a research report on Thursday, July 24th. BNP Paribas raised Zealand Pharma A/S to a "strong-buy" rating in a research report on Tuesday, July 1st. Finally, Barclays raised Zealand Pharma A/S to a "strong-buy" rating in a research report on Monday, July 7th. Five equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy".

Zealand Pharma A/S Trading Down 8.0%

The stock has a market capitalization of $4.67 billion, a PE ratio of 4.62 and a beta of 0.73. The company has a current ratio of 25.10, a quick ratio of 25.07 and a debt-to-equity ratio of 0.03. The stock has a 50 day moving average price of $59.52 and a 200-day moving average price of $66.67.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported $16.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $16.72 by ($0.66). The firm had revenue of $1.43 billion during the quarter, compared to analysts' expectations of $9.18 billion. Zealand Pharma A/S had a return on equity of 82.30% and a net margin of 73.90%. Sell-side analysts expect that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.